Role of Immunoglobulin G in Neuromyelitis Optica Spectrum Disorder
Immunoglobulin G antibodies serve as both the primary diagnostic biomarker and the central pathogenic driver in NMOSD, with aquaporin-4 IgG (AQP4-IgG) defining the most common disease subtype and directly causing complement-mediated astrocyte destruction, while MOG-IgG identifies a distinct disease entity that primarily damages oligodendrocytes. 1, 2
Pathogenic Mechanisms of IgG in NMOSD
AQP4-IgG Mediated Pathology
AQP4-IgG directly targets astrocytes through binding to the aquaporin-4 water channel protein, initiating complement-dependent cytotoxicity (CDC) that leads to astrocyte death, inflammation, and secondary demyelination 3, 2, 4
The pathogenic cascade requires complement activation - AQP4-IgG binding triggers C1q binding and complement activation, which is essential for producing NMOSD lesions in both in vitro and in vivo models 3, 2
Cytotoxicity varies widely among AQP4-IgG positive sera - studies demonstrate that 50% maximum cytotoxicity can be produced by as low as 0.2% serum concentration, though surprisingly 58 of 108 AQP4-IgG positive samples produced no cytotoxicity in experimental models 3
Natural cytoprotective IgG antibodies exist in some patients - approximately 4 of 58 non-cytotoxic sera contained IgG antibodies that actually protected against cytotoxic AQP4-IgG by interfering with pathogenic antibody binding to AQP4, suggesting disease heterogeneity 3
MOG-IgG Mediated Pathology
MOG-IgG defines a distinct disease entity separate from both AQP4-IgG positive NMOSD and multiple sclerosis, characterized by antibodies against full-length, conformationally intact myelin oligodendrocyte glycoprotein 1
MOG-IgG primarily damages oligodendrocytes and myelin rather than astrocytes, causing oligodendrocytopathy through complement-mediated mechanisms distinct from the astrocytopathy seen with AQP4-IgG 2
MOG-IgG requires complement for pathogenicity - in both C57BL/6 mice and Sprague-Dawley rats, MOG-IgG only caused lesions when complement was present, inducing myelin loss as the predominant pathological feature 2
Diagnostic Role of IgG Antibodies
AQP4-IgG Testing
AQP4-IgG seropositivity is the diagnostic hallmark of the most common NMOSD subtype, with antibody presence playing a significant pathogenic role and serving as a key diagnostic marker 5, 6
Higher AQP4-IgG titers correlate with worse disease outcomes - titers positively correlate with age, annual relapse rate, sensory disability scores, activities of daily living impairment, and sleep quality deterioration 7
Late-onset NMOSD patients demonstrate higher AQP4-IgG seropositivity rates and titers compared to early-onset patients, associated with greater disability severity, more sleep disorders, higher anxiety, and poorer cognitive function 7
MOG-IgG Testing
Cell-based assays using full-length human MOG are essential for accurate MOG-IgG detection, as older ELISA methods using denatured MOG peptides produced unreliable results 1
MOG-IgG testing should be selective rather than applied to broad populations, as screening large unselected cohorts significantly reduces positive predictive value and risks overdiagnosis leading to inappropriate treatment 1
MOG-IgG concentrations fluctuate with disease activity - titers are higher during acute attacks than remission, lower during immunosuppression, and may transiently disappear after plasma exchange or IVIG, necessitating re-testing during acute attacks or treatment-free intervals if initially negative 1
MOG-IgG can permanently disappear in some monophasic cases particularly in children with ADEM-like presentations, though it typically persists in patients with relapsing disease courses 1
Therapeutic Implications of IgG Pathogenicity
Antibody-Depleting Therapies
Plasma exchange and immunoadsorption are particularly effective in MOG-IgG positive patients for acute attacks, as these antibody-depleting treatments directly remove pathogenic IgG from circulation 1
B cell-depleting therapies target IgG production - rituximab and other anti-CD20 monoclonal antibodies are effective by eliminating B cells that produce pathogenic antibodies, with good response to these therapies increasing pre-test likelihood of MOG-EM 1
Approved Therapies for AQP4-IgG Positive NMOSD
Four preventive immunotherapies are now approved for AQP4-IgG positive NMOSD: eculizumab, ravulizumab (complement inhibitors), inebilizumab (B cell depletion), and satralizumab (IL-6 receptor blockade) 5, 6
Satralizumab demonstrates sustained effectiveness in real-world Japanese cohorts, reducing annualized relapse rate from 0.45 to 0.03 over 130 weeks with a relapse-free rate of 91.8%, supporting its relapse-preventive effect by blocking IL-6 mediated inflammation 8
Intravenous immunoglobulins may be particularly beneficial in pediatric MOG-IgG positive patients, though IVIG pretreatment can cause false negative and false positive results in antibody assays 1
Clinical Monitoring Considerations
AQP4-IgG titers may predict relapses as median titers are significantly higher during acute attacks than remission, though individual variability limits using titers alone for attack prediction without considering additional factors like blood-CSF barrier damage and T cell activation 1
Regular MOG-IgG monitoring for relapse prediction cannot be generally recommended based on current evidence, as antibody levels rise only very shortly before attacks (similar to AQP4-IgG in NMOSD), requiring impractically frequent testing intervals 1
Re-testing MOG-IgG positive patients 6-12 months after first attack may have prognostic value since antibody disappearance after initial attack might indicate monophasic disease, though titers can fall temporarily with treatment and rise again later, complicating long-term treatment decisions 1